Abstract
With the development of surgical methods and #pharmaceutical preparations, more patients with benign #end-stage lung disease can
receive treatment of lung transplants. Not only the number of surgeries
has increased to 4,000 per year, but also the survival time has been
growing longer. Ten years ago, a lot of medical experts thought that #post-transplant lymphoproliferative disease was a rare disease, but this
disease has received more and more attention because of increasing of
surgeries. PTLD is a serious and rare post-transplant complication.
Compared with other organ transplants, the incidence of heart, lung, and
heart lung transplantation is extremely high. The 5-year survival rate
is 29%, and the median survival period is 10month. Risk factors for
morbidity are related to the use of #immunosuppressive agents, viral
infections, type of transplanted organ, gender, age et al. This article
will describe the incidence, risk factors, pathogenic mechanism,
treatment methods and latest research progress of #lymphoproliferative diseases after lung transplantation recently by providing new ideas on
hotspots. Lung transplantation is the only effective way to treat benign lung
disease of end-stage. Vladimir performed lung transplant surgery on
animals for the first time 70 years ago epically [1]. Soon after, Hardy
did the first human lung transplantation 12 years later [2]. But patient
only lived 42 days after the transplant by limiting to the development
of surgical techniques and drugs. The emergence of immunosuppressants
represented by #cyclosporine (CsA) in 1983 significantly pulled the
survival rate after lung transplantation to a new level. Afterwards, the
median survival time after transplantation can reach 5.3 years [3].
For more articles on BJSTR Journal please click on https://biomedres.us/
For more Psychology Articles on BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.